What is Genelux?
Genelux is a late clinical-stage biopharmaceutical company dedicated to pioneering next-generation oncolytic immunotherapies. Its primary focus is on addressing aggressive and difficult-to-treat solid tumors. The company's lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified vaccinia virus strain currently undergoing evaluation in a Phase 3 registrational trial. This trial, OnPrime/GOG-3076, is assessing Olvi-Vec's efficacy and safety when combined with platinum-doublet and bevacizumab, compared to standard chemotherapy and bevacizumab, for patients with platinum-resistant/refractory ovarian cancer. Genelux's innovation is powered by its proprietary CHOICE platform, which has facilitated the development of an extensive library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec.
How much funding has Genelux raised?
Genelux has raised a total of $20.1M across 2 funding rounds:
Debt
$150K
Debt
$20M
Debt (2020): $150K with participation from PPP
Debt (2020): $20M led by Woodward Diversified Capital
Key Investors in Genelux
Woodward Diversified Capital
Woodward Diversified Capital is an entity that has provided debt financing to Genelux, indicating a focus on capital lending or structured financial instruments.
PPP
Public-Private Partnership
What's next for Genelux?
With substantial enterprise-level funding and a recent strategic investment, Genelux is poised to advance its pipeline of oncolytic immunotherapies. The company's focus on the Phase 3 trial for Olvi-Vec in ovarian cancer suggests a clear path toward potential regulatory approval and commercialization. Continued investment will likely support further clinical development, manufacturing scale-up, and potential expansion into other solid tumor indications. The company's proprietary CHOICE platform provides a robust foundation for future product development, positioning Genelux for sustained growth in the competitive oncology landscape.
See full Genelux company page
